Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dian L Olson

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Molecular Cancer Therapeutics|January 20, 2005
Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine modelDian L Olson, Linda C Burkly, Diane R Leone, et al.
Biochemical and Biophysical Research Communications|October 7, 2008
CRIPTO3, a presumed pseudogene, is expressed in cancerChao Sun, Olivia Orozco, Dian L Olson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2011
An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumoursRebecca K Kelly, Dian L Olson, Yaping Sun, et al.
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Molecular Cancer Therapeutics|January 20, 2005
Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine modelDian L Olson, Linda C Burkly, Diane R Leone, et al.
Biochemical and Biophysical Research Communications|October 7, 2008
CRIPTO3, a presumed pseudogene, is expressed in cancerChao Sun, Olivia Orozco, Dian L Olson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2011
An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumoursRebecca K Kelly, Dian L Olson, Yaping Sun, et al.
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Pageof 1